Carboplatin-gemcitabine in the treatment of elderly patients with non-small cell lung cancer: An outcome analysis
Journal Title: Journal of Cancer Research & Therapy - Year 2015, Vol 3, Issue 10
Abstract
Introduction: To compare a novel carboplatin-gemcitabine (CG) schedule with gemcitabine (G) monochemotherapy in elderly patients with advanced NSCLC. Methods: The records of all the consecutive elderly patients referred to our Department of Oncology for advanced NSCLC were reviewed. Overall survival was the main outcome, time to progression, response rate and safety were the secondary end points. Results: Fifty patients (40 males and 10 females, mean age 75 years, range 68-87 years) were included into the analysis. 30 patients (60%) were treated with the CG and 20 (40%) with G. Median survival was 12.4 months for the entire population, and 14.9 and 5.3 months for CG and G(p=0.043) respectively. 7(14%) and 2(4%) partial regressions were observed in CG and G groups,(p=0.085), with a median time to progression of 5.1 months for the entire population, and 7.3 and 3.5 months for CG and G(p=0.237). Grade III neutropenia was observed in 8(16%) and 2(4%) patients treated with CG and G, respectively; grade IV neutropenia in 2(4%) and 2(4%) patients, grade III anemia in 2(4%) and 1(2%) patients, and grade III thrombocytopenia in 1(2) patient, respectively (p=0.527). Grade II fatigue was observed in 5(10%) and 2(4%) patients, grade III diarrhea in 3(6%) and 1(2%) patients treated with CG and G, respectively (p=0.722). Conclusions: Carboplatin-gemcitabine seems to be more effective that gemcitabine alone in elderly patients with advanced NSCLC, without any worsening of the safety profile. The data, extracted from an outcome analysis, confirm what has been observed in previous clinical trials.
Authors and Affiliations
Fantini M, Stocchi L, Affatato A, Papi M, Sartori S, Ioli G, Lazzari-Agli L, Tassinari D
Keywords
Related Articles
- EP ID EP546095
- DOI 10.14312/2052-4994.2015-16
- Views 65
- Downloads 0
Analysis of Streptococcus bovis infections at a monographic oncological centre
The Streptococcus bovis is a Gram-positive, facultative anaerobic, catalase and oxidase negative coccus belonging to the genus Streptococcus. It is part of Streptoccus bovis/ equinus complex and it express the Lancefield...
CIGB-128, as compassionate intracranial treatment in patients with non-operable or progressive high grade gliomas
Background: High grade glioma (HGG) is the most aggressive and lethal primary brain tumor. The treatment of patients with HGG still remains palliative with improvement in the quality of life and encompasses surgery, radi...
Prophylactic bundle for radiation-induced oral mucositis in oral or oropharyngeal cancer patients
Objective: In order to prevent and treat radiation-induced adverse events, especially oral mucositis, in patients with oral or oropharyngeal cancer receiving radiotherapy or chemoradiotherapy, a prophylactic bundle, i.e....
In vitro and in vivo evaluation of tubulin inhibitors with non-small cell lung cancer pre-clinical models
Synthetic small molecule tubulin inhibitors have many advantages as novel anti-cancer agents compared to the current tubulin inhibitors generated from natural products. Our previous studies led to the design and synthesi...
Atypical presentation of Merkel cell carcinoma positive to polyomavirus DNA detection: Experience from a single center
Merkel cell carcinoma (MCC) is a rare malignant tumor of the skin with tendency to rapid local progression and frequent spread to regional lymph nodes. In this paper we retrospectively describe the atypical presentation...